JP2021505545A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505545A5 JP2021505545A5 JP2020529342A JP2020529342A JP2021505545A5 JP 2021505545 A5 JP2021505545 A5 JP 2021505545A5 JP 2020529342 A JP2020529342 A JP 2020529342A JP 2020529342 A JP2020529342 A JP 2020529342A JP 2021505545 A5 JP2021505545 A5 JP 2021505545A5
- Authority
- JP
- Japan
- Prior art keywords
- a1at
- pharmaceutical composition
- dose
- subject
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 64
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 64
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 64
- 239000008194 pharmaceutical composition Substances 0.000 claims 52
- 238000000034 method Methods 0.000 claims 22
- 150000003431 steroids Chemical class 0.000 claims 11
- 208000024340 acute graft versus host disease Diseases 0.000 claims 10
- 208000007502 anemia Diseases 0.000 claims 9
- 208000032839 leukemia Diseases 0.000 claims 8
- 208000011580 syndromic disease Diseases 0.000 claims 7
- 239000003018 immunosuppressive agent Substances 0.000 claims 6
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 5
- 229960004584 methylprednisolone Drugs 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 206010061598 Immunodeficiency Diseases 0.000 claims 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 208000005980 beta thalassemia Diseases 0.000 claims 4
- 208000022806 beta-thalassemia major Diseases 0.000 claims 4
- 230000003750 conditioning effect Effects 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000003743 erythrocyte Anatomy 0.000 claims 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 4
- 230000007813 immunodeficiency Effects 0.000 claims 4
- 229940125721 immunosuppressive agent Drugs 0.000 claims 4
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 4
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 230000000735 allogeneic effect Effects 0.000 claims 3
- 230000002068 genetic effect Effects 0.000 claims 3
- 230000001172 regenerating effect Effects 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 102100033051 40S ribosomal protein S19 Human genes 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 claims 2
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 2
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 2
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 2
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 2
- 206010049466 Erythroblastosis Diseases 0.000 claims 2
- 102000006395 Globulins Human genes 0.000 claims 2
- 108010044091 Globulins Proteins 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 208000035809 Lymphohistiocytosis Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 230000001919 adrenal effect Effects 0.000 claims 2
- 230000000781 anti-lymphocytic effect Effects 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 229910003460 diamond Inorganic materials 0.000 claims 2
- 239000010432 diamond Substances 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 208000016245 inborn errors of metabolism Diseases 0.000 claims 2
- 229960001810 meprednisone Drugs 0.000 claims 2
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 2
- 230000003458 metachromatic effect Effects 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 2
- 230000000242 pagocytic effect Effects 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 206010033661 Pancytopenia Diseases 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 208000035623 congenital anemia Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023174014A JP2024001191A (ja) | 2017-12-01 | 2023-10-06 | 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593446P | 2017-12-01 | 2017-12-01 | |
| US62/593,446 | 2017-12-01 | ||
| US201862729376P | 2018-09-10 | 2018-09-10 | |
| US62/729,376 | 2018-09-10 | ||
| PCT/US2018/063179 WO2019108865A1 (en) | 2017-12-01 | 2018-11-30 | Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174014A Division JP2024001191A (ja) | 2017-12-01 | 2023-10-06 | 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021505545A JP2021505545A (ja) | 2021-02-18 |
| JP2021505545A5 true JP2021505545A5 (https=) | 2022-01-06 |
Family
ID=64734181
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529342A Pending JP2021505545A (ja) | 2017-12-01 | 2018-11-30 | 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 |
| JP2023174014A Pending JP2024001191A (ja) | 2017-12-01 | 2023-10-06 | 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174014A Pending JP2024001191A (ja) | 2017-12-01 | 2023-10-06 | 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11857610B2 (https=) |
| EP (2) | EP4321220B1 (https=) |
| JP (2) | JP2021505545A (https=) |
| AU (1) | AU2018374285B2 (https=) |
| DK (1) | DK3716998T3 (https=) |
| ES (2) | ES2975208T3 (https=) |
| FI (1) | FI3716998T3 (https=) |
| HR (1) | HRP20240475T8 (https=) |
| HU (1) | HUE066011T2 (https=) |
| PL (1) | PL3716998T3 (https=) |
| PT (1) | PT3716998T (https=) |
| SI (1) | SI3716998T1 (https=) |
| WO (1) | WO2019108865A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021028927A1 (en) * | 2019-08-15 | 2021-02-18 | Kamada Ltd | Combination of alpha-1-antitrypsin and steroids and uses therefor |
| WO2023056075A1 (en) * | 2021-10-01 | 2023-04-06 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for reduced toxicity in transplantation using janus kinase (jak) inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9457070B2 (en) * | 2005-06-07 | 2016-10-04 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease |
| US8715649B2 (en) | 2005-06-07 | 2014-05-06 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity |
| US20090118162A1 (en) | 2005-06-07 | 2009-05-07 | Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival |
| CN101341254A (zh) * | 2005-12-24 | 2009-01-07 | 蒂加斯克乳制品研究中心 | 反-10，顺-12十八碳二烯酸的生产方法 |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| CA2798518A1 (en) * | 2010-05-17 | 2011-11-24 | Cebix, Inc. | Pegylated c-peptide |
| EP3628327A1 (en) * | 2011-06-24 | 2020-04-01 | The Regents of the University of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| US10400029B2 (en) * | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| CN110551223A (zh) | 2011-06-28 | 2019-12-10 | 英伊布里克斯有限合伙公司 | 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法 |
| AU2013202648B2 (en) | 2012-01-10 | 2016-05-19 | Konkuk University | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| ES2799153T3 (es) | 2013-03-29 | 2020-12-15 | Univ Colorado Regents | Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante |
| WO2017117558A1 (en) | 2015-12-31 | 2017-07-06 | The Regents Of The University Of Colorado, A Body Corporate | Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications |
-
2018
- 2018-11-30 PT PT188218515T patent/PT3716998T/pt unknown
- 2018-11-30 PL PL18821851.5T patent/PL3716998T3/pl unknown
- 2018-11-30 DK DK18821851.5T patent/DK3716998T3/da active
- 2018-11-30 HR HRP20240475TT patent/HRP20240475T8/hr unknown
- 2018-11-30 SI SI201831084T patent/SI3716998T1/sl unknown
- 2018-11-30 JP JP2020529342A patent/JP2021505545A/ja active Pending
- 2018-11-30 EP EP23209713.9A patent/EP4321220B1/en active Active
- 2018-11-30 US US16/768,281 patent/US11857610B2/en active Active
- 2018-11-30 HU HUE18821851A patent/HUE066011T2/hu unknown
- 2018-11-30 WO PCT/US2018/063179 patent/WO2019108865A1/en not_active Ceased
- 2018-11-30 FI FIEP18821851.5T patent/FI3716998T3/fi active
- 2018-11-30 AU AU2018374285A patent/AU2018374285B2/en active Active
- 2018-11-30 ES ES18821851T patent/ES2975208T3/es active Active
- 2018-11-30 ES ES23209713T patent/ES3059603T3/es active Active
- 2018-11-30 EP EP18821851.5A patent/EP3716998B1/en active Active
-
2023
- 2023-10-06 JP JP2023174014A patent/JP2024001191A/ja active Pending
- 2023-11-20 US US18/513,964 patent/US20240238395A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schmitt et al. | Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients | |
| Busca et al. | Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation | |
| Nash et al. | A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation | |
| McCaul et al. | Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin | |
| McKeage et al. | Basiliximab: a review of its use as induction therapy in renal transplantation | |
| Jaime-Pérez et al. | Danazol as first-line therapy for aplastic anemia | |
| Daly et al. | Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants | |
| Peters et al. | Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children | |
| Herold et al. | Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab | |
| JP2021107423A (ja) | カンパス−１Ｈ（Ｃａｍｐａｔｈ−１Ｈ）による多発性硬化症（ＭＳ）治療 | |
| JP2021505545A5 (https=) | ||
| Iskierka-Jażdżewska et al. | New treatment options for newly-diagnosed and relapsed chronic lymphocytic leukemia | |
| Grillo-López | Monoclonal antibody therapy for B-cell lymphoma | |
| Deierhoi et al. | A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection | |
| TWI899057B (zh) | 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑 | |
| US20250114360A1 (en) | Novel regimen for augmenting and extending transplant tolerance | |
| JP2024001191A (ja) | 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 | |
| US20240101671A1 (en) | Method and composition for inducing tolerance | |
| Lutfi et al. | The emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas | |
| Naik et al. | Cyclophosphamide for refractory acute cellular rejection after lung transplantation | |
| Namdaroglu et al. | The role of ruxolitinib in the management of acute GVHD | |
| Denfield | Strategies to prevent cellular rejection in pediatric heart transplant recipients | |
| Shigemura et al. | Comparative analysis of graft-versus-host disease prophylaxis with tacrolimus in combination with methylprednisolone or methotrexate after umbilical cord blood transplantation | |
| Uslu et al. | Two-day induction with thymoglobulin in kidney transplantation: risks and benefits | |
| Ringdén | Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors |